Clinical trials: Cancer Patient
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The purpose of this study is to examine the safety and efficacy of Ibrutinib administered in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small…
- Trial name
- NCT01611090
- Testing
- Ibrutinib, Bendamustine hydrochloride, Rituximab
- Where
- 155 sites in United States, Argentina and 19 more
- Volunteers
- 578 people
- Sponsor
- Janssen Research & Development, LLC
Melanoma
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
The purpose of this clinical study is to examine the safety, immunogenicity and clinical activity of the immunotherapeutic product GSK2302025A (also referred to as recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic [ASCI])…
- Trial name
- NCT01149343
- Testing
- Immunotherapeutic GSK2302025A, different formulations
- Where
- 37 sites in Czechia, France and 4 more
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
This randomized phase III trial is studying donor bone marrow transplant with or without G-CSF to compare how well they work in treating young patients with hematologic cancer or other diseases.
- Conditions
- Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes
- Trial name
- NCT00450450
- Testing
- allogeneic bone marrow transplantation, laboratory biomarker analysis, filgrastim
- Where
- 21 sites in United States
- Volunteers
- 27 people
- Sponsor
- Children's Oncology Group
Prostate Cancer
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
The study was a three-arm, active-control, multi-centre, parallel group study.
- Trial name
- NCT00295750
- Testing
- Degarelix, Leuprolide 7.5 mg
- Where
- 35 sites in United States, Canada and 10 more
- Volunteers
- 620 people
- Sponsor
- Ferring Pharmaceuticals
Colorectal Cancer
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01079780
- Testing
- cetuximab, ramucirumab, irinotecan hydrochloride
- Where
- 255 sites in United States
- Volunteers
- 136 people
- Sponsor
- Eastern Cooperative Oncology Group
Oncology, Adapted Physical Activity
Feasibility of Adapted Physical Activity Based on a Walking Platform in Hospitalized Old Patients for Cancer
The investigator propose to evaluate the interest of the provision of a suitable treadmill offering fall protection and verticalization assistance.
- Trial name
- APPAHOCA (NCT03473652)
- Testing
- Adapted walking platform
- Where
- 2 sites in France
- Volunteers
- 45 people
- Sponsor
- Centre Francois Baclesse
Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma
Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Stage IV Endometrial Carcinoma
- Trial name
- NCT00095979
- Testing
- ixabepilone
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
This phase II trial studies how well dinutuximab works when given with sargramostim in treating patients with osteosarcoma that has come back after treatment (recurrent).
- Conditions
- Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma
- Trial name
- NCT02484443
- Testing
- Dinutuximab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 130 sites in United States, Australia and 3 more
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases
This is an open-label, single centre, Phase I study to determine the brain exposure of [11C]osimertinib in patients with EGFRm NSCLC with brain metastases.
- Trial name
- ODIN-BM (NCT03463525)
- Testing
- Osimertinib, [11C]osimertinib
- Where
- Sweden
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Small-Cell Lung Cancer
Study of AZD2811 + Durvalumab in ES-SCLC
A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with…
- Trial name
- TAZMAN (NCT04745689)
- Testing
- Durvalumab, AZD2811, Carboplatin
- Where
- 12 sites in United States, Poland and 2 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Colorectal Cancers
Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared to Best Supportive Care in Colorectal Cancer Patients
This is a clinical research study of an investigational (FDA IND-BB 10091) treatment for patients with advanced colorectal cancer that no longer responds to standard therapies.
- Trial name
- NCT02046174
- Testing
- RENCA macrobeads
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- The Rogosin Institute
Prostate Cancer
Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00619515
- Testing
- questionnaire administration, implanted fiducial-based imaging, stereotactic radiosurgery
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- Case Comprehensive Cancer Center
Pancreatic Cancer
Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
This is a phase II, multicenter, double-blinded, randomized, 2-arm trial evaluating the efficacy and safety of mFOLFIRINOX plus ramucirumab (Arm A) vs.
- Trial name
- NCT02581215
- Testing
- mFOLFIRINOX, Ramucirumab
- Where
- 8 sites in United States
- Volunteers
- 84 people
- Sponsor
- Walid Shaib, MD
Colorectal Cancer
Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00290615
- Testing
- bevacizumab, cetuximab, capecitabine
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Herbert Hurwitz
Accelerated Phase Chronic Myelogenous Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
This phase II trial is studying how well giving 3-AP together with fludarabine works in treating patients with myeloproliferative disorders (MPD), chronic myelomonocytic leukemia (CMML), or accelerated phase or blastic phase…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia
- Trial name
- NCT00381550
- Testing
- fludarabine phosphate, triapine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Breast Neoplasms
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
This phase II trial studies the efficacy of trastuzumab treatment in breast cancer patients with stage II-III human epidermal growth factor receptor 2 (HER2)-negative tumors and HER2-expressing bone marrow disseminated tumor…
- Trial name
- NCT01779050
- Testing
- Doxorubicin, Trastuzumab, Cyclophosphamide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Washington University School of Medicine
Leukemia, Fungal Infection
Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia
The goal of this clinical research study is to learn the amount of posaconazole that is in the body at different time points when given to patients with leukemia. The safety of this drug will also be studied.
- Trial name
- NCT00936117
- Testing
- Posaconazole
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Non-Small Cell Lung Cancer
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab in combination with erlotinib as compared to placebo in combination with erlotinib in previously untreated participants with stage IV non-small…
- Trial name
- RELAY (NCT02411448)
- Testing
- Ramucirumab, Erlotinib, Gefitinib
- Where
- 106 sites in United States, Canada and 12 more
- Volunteers
- 545 people
- Sponsor
- Eli Lilly and Company
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.
- Trial name
- NCT03430843
- Testing
- Tislelizumab, Paclitaxel, Docetaxel
- Where
- 104 sites in United States, Belgium and 9 more
- Volunteers
- 512 people
- Sponsor
- BeiGene
Kidney Cancer
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00589550
- Testing
- PEG-interferon alfa-2b, Sorafenib, gene expression analysis
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Thomas Olencki
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.